CD274 and neoplasm: Some clinical studies have shown that PDL1-negative patients tend to have lower tumor mutation burdens or fewer neoantigens than PDL1-positive patients (Xia et al., 2017; Chan et al., 2019), which might be related to its involvement in various repair systems.